Does C79.82 require prior authorization?

No, C79.82 does not require prior authorization (high confidence). Code is covered without prior authorization.

`C79.82` — Secondary malignant neoplasm of genital organs

ICD-10-CM

No Prior Auth Required

Code is covered without prior authorization (high confidence)

The supplier must enter a diagnosis code corresponding to the beneficiary's cancer diagnosis on each claim for oral antiemetic drugs.
A written, signed, and dated order must be received by the supplier before a claim is submitted for any oral antiemetic drug.
Claims for oral aprepitant (J8501), rolapitant (J8670) or netupitant/palonosetron (J8655) must also be accompanied by a diagnosis code indicating an encounter for antineoplastic chemotherapy.
Claims billed for code Q0181 must include drug name, manufacturer, dosage strength dispensed, each tablet/suppository/etc, and frequency of administration during the covered time period entered in the narrative field of an electronic claim.

An oral antiemetic drug is covered when it has been ordered by the treating practitioner as part of a cancer chemotherapy regimen.
An oral antiemetic drug is covered when the drug is FDA‑approved for use as an antiemetic.
An oral antiemetic drug is covered when it is used as a full therapeutic replacement for an intravenous antiemetic that would otherwise have been administered at the time of the chemotherapy treatment.
An oral antiemetic drug is covered when it is initiated within two hours of administration of the chemotherapeutic agent and continued no more than 48 hours from that time.
A 3‑drug regimen (NK‑1 antagonist + 5HT3 antagonist + dexamethasone) is covered when all four coverage criteria are met and all three drugs are given in combination.
Netupitant/palonosetron (fixed combination) is covered when given in conjunction with dexamethasone without requiring a separate 5HT3 antagonist, provided the general coverage criteria are met.

L39709 — MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers

J05

A59549 — Billing and Coding: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers

J05

A55147 — Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID Update

J05

A55162 — Billing and Coding: MolDX: FDA-Approved KRAS Tests

J05

Ask Verity about documentation requirements, denial risks, or coverage in your state.